Issue: March 2017, Posted Date: 3/23/2017
Aptar Pharma's Preservative-Free Multidose Dispenser Chosen for the First Time
Pharma’s innovative and patented preservative-free multidose Ophthalmic Squeeze
Dispenser is available for patients in the US prescription market for the first
time with Allergan’s RESTASIS MULTIDOSE (Cyclosporine Ophthalmic Emulsion)
approval and launch makes the Aptar Pharma Ophthalmic Squeeze Dispenser the
very first, and only, US FDA-approved multidose delivery system to handle
prescription eye treatment formulations without any preservatives.
Photo Courtesy of
Aptar Pharma is working closely
with eye care specialist Allergan to improve patient safety, achieve dosing
accuracy, and maintain product integrity. Dry eye
patients use eye drops on a regular basis, and often for the rest of their
lives. It is well-proven that preserved medications may cause unpleasant and
sometimes serious side effects.
increasing number of patients experiencing eye irritation or allergic reactions
with preserved formulations appreciate the fact that preservatives can be
removed from eye care medications with Aptar Pharma’s Ophthalmic Squeeze
Dispenser system. RESTASIS and RESTASIS MULTIDOSE are FDA-approved prescription
treatments to help patients suffering from Chronic Dry Eye to make more of
their own tears.
Aptar Pharma’s Ophthalmic
Squeeze Dispenser system is the result of more than 10 years of development and
experience in the delivery of preservative-free ophthalmic solutions. Patients
and consumers in Europe, Latin America, and Asia have benefited from this
technology since 2012 with more than 100 commercial references now available on
the market. RESTASIS is not an artificial tear. It is a prescription medicine
that helps increase the eyes' natural ability to produce tears.
Ophthalmic Squeeze Dispenser technology has been a great success for our
customers,” explained Salim Haffar, President, Aptar Pharma. “The proven and
unrivalled microbiological safety, combined with a precise and reproducible
drop ejection allows pharmaceutical customers worldwide to enter into
discussions with regulatory agencies such as the FDA.”
Haffar also points out the user-friendliness of the system, “The ergonomic and
pocket-size design and the intuitiveness of a squeezable container with a low
actuation force certainly contribute to the high levels of acceptance among
patients and consumers around the world.”
Pharma's Ophthalmic Squeeze Dispenser provides a unique competitive advantage
by addressing the global trend toward patient-friendly, cost-effective, and
preservative-free multidose dispensers.
Pharma is part of AptarGroup, Inc., a leading global supplier of a broad range
of innovative dispensing and sealing solutions for the beauty, personal care,
home care, prescription drug, consumer healthcare, injectables, food and
beverage markets. AptarGroup is headquartered in Crystal Lake, IL, with
manufacturing facilities in North America, Europe, Asia, and South America. For
more information, visit aptar.com/pharma.
This record has been viewed 441 times.